Trial · NCT06967012
A Clinical Study on the Efficacy and Safety of Zonisamide as a First Add-On Treatment in Epileptic Seizures
NCT06967012, Phase 4, Recruiting, Affiliated Hospital of Nantong University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Clinical Study on the Efficacy and Safety of Zonisamide as a First Add-On Treatment in Epileptic Seizures. Trials, record NCT06967012. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06967012
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Clinical Study on the Efficacy and Safety of Zonisamide as a First Add-On Treatment in Epileptic Seizures
- NCT number
- NCT06967012
- Status
- Recruiting
- Phases
- Phase 4
- Enrollment
- 30 participants, estimated
- Lead sponsor
- Affiliated Hospital of Nantong University
- Conditions
- Epilepsies, Partial, Epilepsy, Tonic-Clonic
- Interventions
- Oral Zonisamide Therapy
- First posted
- 2025-05-13
- Last updated
- 2025-05-13
Source ClinicalTrials.gov
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Primary Observational Indicators | Week 0±7day, Week 8±7day, Week 20±7day | Change in seizure frequency: The reduction in seizure frequency over an average of four weeks during the maintenance period, compared with the retrospective baseline period, in patients with focal epilepsy with or without secondary generalized tonic-clonic seizures. |
| Primary | Primary Observational Indicators | Week 0±7day, Week 8±7day, Week 20±7day | ≥50% response rate: The proportion of subjects achieving a ≥50% reduction in the average four-week seizure frequency during the maintenance period compared to the retrospective baseline period in patients with focal epilepsy with or without secondary generalized tonic-clonic seizures. |
| Secondary | Secondary Observational Indicators | Week 0±7day, Week 8±7day, Week 20±7day | 1. The percentage of patients achieving seizure-free status during the maintenance period in patients with focal epilepsy with or without secondary generalized tonic-clonic seizures. 2. Retention rate: The percentage of patients who continue to take the medication within a specific time compared to the initial number of patients who started the medication. |
| Secondary | Safety Evaluation | Week 0±7day, Week 8±7day, Week 20±7day | Weight (kg) |
| Secondary | Safety Evaluation | Week 0±7day, Week 8±7day, Week 20±7day | blood pressure (mmHg) |
| Secondary | Safety Evaluation | Week 0±7day, Week 8±7day, Week 20±7day | Pulse (bpm) |
| Secondary | Safety Evaluation | Week 0±7day, Week 8±7day, Week 20±7day | Blood routine: WBC (/L), PLT (/L) |
| Secondary | Safety Evaluation | Week 0±7day, Week 8±7day, Week 20±7day | Liver function: ALT (U/L), AST (U/L), ALP (U/L) |
| Secondary | Safety Evaluation | Week 0±7day, Week 8±7day, Week 20±7day | Kidney function: Scr(μmol/L) |
| Secondary | Safety Evaluation | Week 0±7day, Week 8±7day, Week 20±7day | Blood routine: Hb (g/L) |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 38822293 | BACKGROUND |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06967012
GET https://conductscience.org/api/trials/v1/NCT06967012/registered